GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » Beneish M-Score

FibroGen (FibroGen) Beneish M-Score : -0.85 (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is FibroGen Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.85 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for FibroGen's Beneish M-Score or its related term are showing as below:

FGEN' s Beneish M-Score Range Over the Past 10 Years
Min: -5.36   Med: -3.04   Max: 7.68
Current: -0.85

During the past 12 years, the highest Beneish M-Score of FibroGen was 7.68. The lowest was -5.36. And the median was -3.04.


FibroGen Beneish M-Score Historical Data

The historical data trend for FibroGen's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Beneish M-Score Chart

FibroGen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.44 -5.36 7.68 -4.44 -0.85

FibroGen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.44 -4.27 -3.08 -1.32 -0.85

Competitive Comparison of FibroGen's Beneish M-Score

For the Biotechnology subindustry, FibroGen's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where FibroGen's Beneish M-Score falls into.



FibroGen Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of FibroGen for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.3991+0.528 * 0.9811+0.404 * 0.9239+0.892 * 1.0499+0.115 * 0.8761
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8804+4.679 * 0.102461-0.327 * 1.4527
=-0.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $41.1 Mil.
Revenue was 27.138 + 40.134 + 44.319 + 36.161 = $147.8 Mil.
Gross Profit was 21.731 + 35.891 + 38.611 + 32.67 = $128.9 Mil.
Total Current Assets was $331.6 Mil.
Total Assets was $423.5 Mil.
Property, Plant and Equipment(Net PPE) was $81.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $9.9 Mil.
Selling, General, & Admin. Expense(SGA) was $115.3 Mil.
Total Current Liabilities was $217.7 Mil.
Long-Term Debt & Capital Lease Obligation was $138.5 Mil.
Net Income was -56.232 + -63.615 + -87.68 + -76.705 = $-284.2 Mil.
Non Operating Income was 0 + -12.606 + 0 + 0 = $-12.6 Mil.
Cash Flow from Operations was -18.321 + -84.538 + -110.571 + -101.591 = $-315.0 Mil.
Total Receivables was $16.3 Mil.
Revenue was 34.367 + 15.735 + 29.806 + 60.827 = $140.7 Mil.
Gross Profit was 29.442 + 11.427 + 22.997 + 56.589 = $120.5 Mil.
Total Current Assets was $492.8 Mil.
Total Assets was $610.1 Mil.
Property, Plant and Equipment(Net PPE) was $100.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $10.6 Mil.
Selling, General, & Admin. Expense(SGA) was $124.7 Mil.
Total Current Liabilities was $273.6 Mil.
Long-Term Debt & Capital Lease Obligation was $79.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(41.053 / 147.752) / (16.299 / 140.735)
=0.277851 / 0.115813
=2.3991

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(120.455 / 140.735) / (128.903 / 147.752)
=0.855899 / 0.872428
=0.9811

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (331.559 + 81.219) / 423.529) / (1 - (492.826 + 100.498) / 610.087)
=0.025384 / 0.027476
=0.9239

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=147.752 / 140.735
=1.0499

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(10.604 / (10.604 + 100.498)) / (9.93 / (9.93 + 81.219))
=0.095444 / 0.108943
=0.8761

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(115.252 / 147.752) / (124.69 / 140.735)
=0.780037 / 0.885991
=0.8804

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((138.471 + 217.668) / 423.529) / ((79.593 + 273.562) / 610.087)
=0.840885 / 0.57886
=1.4527

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-284.232 - -12.606 - -315.021) / 423.529
=0.102461

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

FibroGen has a M-score of -0.85 signals that the company is likely to be a manipulator.


FibroGen Beneish M-Score Related Terms

Thank you for viewing the detailed overview of FibroGen's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen (FibroGen) Business Description

Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Executives
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno director, officer: Chief Executive Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Thane Wettig officer: Chief Commercial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Christine Chung officer: SVP, China Operations C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Benjamin Cravatt director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Suzanne Blaug director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James A Schoeneck director C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Mark Eisner officer: Incoming Chief Medical Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham officer: Chief Financial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr director P O BOX 587, WARSAW IN 46581-0587
Pat Controneo officer: VP, Finance and CFO C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi director C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158

FibroGen (FibroGen) Headlines

From GuruFocus

FibroGen Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-08-2023